Effectiveness of Transcranial Magnetic Stimulation (TMS) in Smoking Cessation, Combining Withdrawal Stimulation Followed by Maintenance Stimulation to Prevent Relapse.

Smoking Cessation Clinical Trial

— TabacStim2  

Official title:

Effectiveness of Transcranial Magnetic Stimulation (TMS) in Smoking Cessation, Combining Withdrawal Stimulation Followed by Maintenance Stimulation to Prevent Relapse: Single-center, Randomized, Controlled, Blinded Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04591743
• Other study ID #: TROJAK CRBFC-E 2019
• Status: Completed
• Phase: N/A
• Start date: June 29, 2020
• Est. completion date: October 7, 2022

Study information

• Verified date: February 2024
• Source: Centre Hospitalier Universitaire Dijon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Tobacco control is a Public Health priority. Tobacco is directly responsible for 75,000 deaths per year in France. Without help, less than 5% of smokers are still abstinent within 12 months of quitting. The use of nicotine substitutes only increases the chances of success in smoking cessation by 2 to 3%.

Brain imaging research shows that the dorsolateral prefrontal cortex (DLPFC) is involved in tobacco addiction. Disorders induced in the CPFDL cause an irrepressible desire to smoke (craving) and explain a large part of the relapse at the time of smoking cessation.

Transcranial magnetic stimulation (TMS) could be promising in smoking cessation. This technique allows direct stimulation of the DLPFC via a magnetic coil, so as to reduce the cortical activity of the DLPFC, and thus reduce tobacco craving.

A first randomized controlled study was conducted at the Dijon University Hospital in Dijon in smokers who were heavily addicted and who had failed with the usual withdrawal strategies. In this study, it was found that the combination of nicotine substitutes (to reduce the physical symptoms of withdrawal) with 10 sessions of TCS (to reduce craving) made it possible to maintain abstinence from tobacco during the first 2 weeks of withdrawal (% abstinence = 88.8% active TCS group vs. 50% placebo TCS group; p=0.027).

However, in this study, the therapeutic effect of the nicotine-TCS combination was not prolonged once the stimuli stopped. At 6 and 12 weeks from the start of withdrawal, abstinence rates in the active SMT and placebo SMT groups were no longer significantly different.

It is therefore proposed to renew the protocol by adding maintenance brain stimulation to the initial protocol. Used in the treatment of depression, the maintenance brain stimuli could increase the chances of smoking cessation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 79
• Est. completion date: October 7, 2022
• Est. primary completion date: October 7, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient who has given oral consent

• Adult patient

• Patient wishing to stop smoking

• Patient highly addicted to nicotine (= score 7 on Fagerström's self-questionnaire*)

• Patient with at least 1 previous smoking cessation failure using recommended drug therapies (nicotine, vareniciline, bupropion)

Exclusion Criteria:

• Patient not affiliated or not benefiting from national health insurance

• Person deprived of their liberty by judicial or administrative decision

• Protected adults (curatorship, guardianship)

• Pregnant, parturient or breastfeeding woman

• Patient of childbearing age with a positive pregnancy test at inclusion

• Major patient incapable or unable to express consent

• Patient abstinent in the previous 3 months

• Patient with a substance use disorder (DSM-5 criteria) with other psychoactive substances other than tobacco

• Patient with a contraindication to the practice of TCS; personal history of seizure, pacemaker, neurosurgical clips, carotid or aortic clips, heart valves, hearing aid, ventricular bypass valve, sutures with wires or staples, foreign bodies in the eye, shrapnel, other prosthesis or cephalic ferromagnetic material.

• Patient employed by the investigator or trial site

• Patient with severe depression, defined by a score greater than or equal to 24 on the Hamilton Depression Rating Scale

• Patient who has had a recent change (< 1 month) in the prescription of psychotropic treatment

• Patient with severe and/or chronic psychiatric disorders, including schizophrenia, paranoia, and bipolar disorders type I and II.

• Patient with severe heart, kidney, liver or lung failure or other condition that the physician believes may compromise the patient's participation in the study.

• Patient simultaneously participating in another therapeutic trial

Related Conditions & MeSH terms

• Recurrence
• Smoking Cessation

Intervention

Device:
• Active TCS
TCS active at 1 Hz on the right DLPFC for 6 weeks
• Placebo TCS
Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks

Drug:
• nicotine treatment
at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)

Other:
• Questionnaires
EVA on "craving", TCQ, QSU, BDI-II, CO tester, IGT, BART

Locations

Country	Name	City	State
France	Chu Dijon Bourgogne	Dijon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Continuous Abstinence Rate	Continuous Abstinence Rate within 6 weeks of starting to quit smoking	Through study completion, an average of 12 months